{"filing":{"accession_number":"0001654954-26-008520","cik":"0000901832","ticker":"AZN","company_name":"ASTRAZENECA PLC","form":"6-K","filing_date":"2026-09-23","report_date":"2026-09-23","primary_document":"a8652v.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/901832/000165495426008520/a8652v.htm"},"events":[{"id":34438,"run_id":31682,"accession_number":"0001654954-26-008520","anchor_item_number":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"AstraZeneca announces European Commission approval of Trixeo (budesonide/glycopyrronium/formoterol) for asthma maintenance treatment in patients 12 years and older. This is a significant regulatory milestone and product approval that expands the company's respiratory portfolio and addresses a large unmet medical need (43 million asthma patients in Europe). While not fitting a discrete event category like M\u0026A or earnings, this material regulatory approval of a new indication for an established product is a key operational and commercial milestone that would affect investor assessment of the company's growth prospects and pipeline execution.","company_name":"ASTRAZENECA PLC","ticker":"AZN","filing_date":"2026-09-23","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":38160,"accession_number":"0001654954-26-008520","item_number":null,"item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"AstraZeneca announces European Commission approval of Trixeo (budesonide/glycopyrronium/formoterol) for asthma maintenance treatment in patients 12 years and older. This is a significant regulatory milestone and product approval that expands the company's respiratory portfolio and addresses a large unmet medical need (43 million asthma patients in Europe). While not fitting a discrete event category like M\u0026A or earnings, this material regulatory approval of a new indication for an established product is a key operational and commercial milestone that would affect investor assessment of the company's growth prospects and pipeline execution.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-23T10:05:47.370606+00:00","company_name":"ASTRAZENECA PLC","ticker":"AZN","filing_date":"2026-09-23"}]}